Recent posts
Insurers spend $30 billion annually on workers compensation claims; lost productivity saps another $60 billion from the economy. San Diego-based NextImage Medical is focused on changing this picture by taking aim... Read more »
Somaxon Pharmaceuticals overcame two regulatory delays to win FDA approval to market its insomnia drug doxepin (Silenor). Now comes the hard part.
San Diego-based Somaxon (NASDAQ: SOMX) is entering a... Read more »
Cyntellect, a San Diego-based company working on technologies to analyze, purify and process cells, raised $3 million from the sale of debt, equity and options or warrants, according to an SEC... Read more »
Regulatory and funding headlines dominated a light week. It’s summarized for you here.
—Torrey Pines Investment raised $30 million for a second venture fund that aims to raise a total... Read more »
Elcelyx Therapeutics of San Diego has raised $1.2 million of a planned $2.2 million equity offering, according to an SEC filing. The document says the company’s president is Alain D.... Read more »
Regulatory news dominated the headlines in the past week. We have it summarized for you here.
—Sequenom (NASDAQ: SQMN) said a lack of adequate controls, protocols and supervision were... Read more »
Things were hopping over the past week in San Diego. Get into the rhythm here.
—San Diego’s West Wireless Health Institute named Donald Casey chief executive officer. Casey was formerly... Read more »
Acadia Pharmaceuticals of San Diego and its Canadian partner Biovail are continuing to move ahead with pimavanserin. The experimental drug, you might recall, failed last September in a trial testing it... Read more »
[Updated 2/26/10, 1:30 pm. See below.] The FDA has told San Diego-based Novalar to stop using a misleading patient brochure promoting the company’s injectible dental drug, phentolamine mesylate, which... Read more »
Staying in business was a challenge for La Jolla Pharmaceutical. Going out of business may be harder still.
After its lead drug candidate bombed last year in a clinical trial, La... Read more »
There was a smorgasbord of announcements in the last week. Get your fill here.
—Anadys Pharmaceuticals (NASDAQ: ANDS) said preliminary findings from a mid-stage trial in hepatitis C patients... Read more »
San Diego-based Cadence (NASDAQ: CADX) disclosed two weeks ago that the FDA could not approve the company’s pain reliever because of manufacturing problems, but the company didn’t provide any details.... Read more »
With hundreds of biotechnology companies and thousands of people employed in life sciences, San Diego has a large, informal network of people with deep knowledge across a wide range of skills.... Read more »
Some local biotechnology companies landed funding deals during the past week. We’ve got that and other highlights below.
—Tioga Pharmaceuticals raised $18 million in private equity to fund a late-stage clinical... Read more »
Tioga Pharmaceuticals, a virtual company based in San Diego with just two fulltime employees, is announcing today it has raised $18 million in private equity to fund a late-stage clinical... Read more »
Cadence Pharmaceuticals’ plans to market an intravenous form of acetaminophen received another regulatory setback today. The FDA told the San Diego-based company that it could not approve the drug because of... Read more »
There was a steady flow of drug development and funding news from San Diego’s life sciences industry over the past week. Here are the highlights.
—Halozyme Therapeutics (NASDAQ: HALO)... Read more »
Lifevantage (OTCBB: LFVN), a San Diego-based nutraceuticals company, raised $2.6 million of a $5 million securities offering that included debt and options, warrants or other rights to acquire another security,... Read more »
Cellulite is the bane of women everywhere. Caused by the irregular tightening of connective fibers between the muscle and skin, cellulite mars the rump and thighs with uneven dimples and bulges,... Read more »
Fragile X syndrome is the second leading cause of mental retardation, after Down syndrome. Caused by a defect on the X chromosome, the syndrome affects boys more frequently and severely than... Read more »
